Product Description
AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune).
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Adimmune
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ADPCT21013I | P2 |
Completed |
COVID-19 |
2022-12-29 |
25% |
| ADPCT20011X | P1 |
Completed |
COVID-19 |
2020-11-20 |
70% |